The US Government Bought Equity in 9 Quantum Companies. Their Combined Revenue Wouldn't Cover One F-35 Engine.
The Commerce Department is investing $2.013 billion from the CHIPS and Science Act in quantum computing, taking minority equity stakes in nine companies whose combined annual revenue totals roughly $169 million. At a sector-wide price-to-sales ratio of 334x, these stocks trade at 48 times the NASDAQ's valuation at the peak of the dot-com bubble. An original analysis. Who gets the money, who shaped the program, and what the announcement itself did to stock prices.
$169 million. Stop there. That is the combined annual revenue of the four publicly traded pure-play quantum computing companies in the United States: IonQ ($130M), D-Wave ($24.6M), Rigetti ($7.1M), and Quantinuum (estimated $7M pre-IPO). Their combined market capitalization as of July 1, 2026: $56.5 billion, a figure that tells you everything about where quantum stands right now. Run the math: $56.5B ÷ $169M = a sector price-to-sales ratio of 334x, a number so extreme that comparing it to the dot-com bubble actually undersells the absurdity. At the NASDAQ's peak in March 2000, the composite traded at roughly 7x sales, and Cisco, the poster child of that era, topped out at 40x. Quantum blows past every one of them. And the US government just bought in.
On May 21, 2026, the Department of Commerce announced letters of intent to provide $2.013 billion in CHIPS and Science Act incentives to nine quantum computing companies, taking minority equity stakes in exchange. These are not finalized agreements and remain contingent on milestones and performance targets that neither Commerce nor the recipients have disclosed publicly, but the structure itself is unmistakable. Not grants. Not subsidies. Equity. Ownership.
Where the $2 Billion Goes
Lopsided. 68% of the funding goes to two foundry companies. Two. IBM and GlobalFoundries together collect $1.375 billion of the $2.013 billion total, leaving the seven actual quantum computing companies to divide $638 million among themselves, which works out to an average of $91 million per company for businesses operating at the outer edge of physical possibility. As deep-tech analyst Alan Gorenstein wrote on LinkedIn: "Everyone is reading the $2B quantum announcement wrong. It is not a bet on qubits. It is a bet on foundries."
| Company | Award | Modality | Market Cap | FY2025 Revenue |
|---|---|---|---|---|
| IBM (Anderon) | $1,000M | Superconducting (foundry) | $261B | $67.5B |
| GlobalFoundries | $375M | Multi-modal (foundry) | $30B | $7.3B |
| Quantinuum | $100M | Trapped ion | $21.3B | ~$7M* |
| IonQ | $0 | Trapped ion | $19.9B | $130M |
| D-Wave | $100M | Superconducting | $8.9B | $24.6M |
| Rigetti | $100M | Superconducting | $6.4B | $7.1M |
| Atom Computing | $100M | Neutral atom | Private | Private |
| Infleqtion | $100M | Neutral atom | Private | Private |
| PsiQuantum | $100M | Photonic | Private | Private |
| Diraq | $38M | Silicon spin | Private | Private |
| Total | $2,013M |
*Quantinuum revenue estimated from pre-IPO Honeywell disclosures. Market caps as of July 1, 2026, sourced from public exchange data.
IonQ, the largest quantum pure-play by revenue at $130 million annually, was left out entirely; Barron's reported that Honeywell's recently IPO'd spinoff Quantinuum took the trapped-ion slot instead.
IBM's Revolving Door
IBM received $1 billion of the $2 billion total — half. It will build a subsidiary called Anderon, a 300mm quantum wafer foundry in Albany, matched with $1 billion of its own capital plus IP and personnel transfers. Darío Gil, who oversees quantum strategy at the Department of Energy as Under Secretary for Science since September 2025, spent 22 years at IBM before that appointment, rising to SVP and Director of Research in the division whose commercial successor now receives the program's single largest share.
Rep. Zoe Lofgren (D-CA) raised the conflict directly: Gil "was involved in discussions surrounding the awards while IBM emerged as the largest beneficiary." She also challenged the legal basis, arguing that Section 102 of the CHIPS Act authorized microelectronics research, not quantum manufacturing incentives or government equity stakes.
Gil's defenders have a point. IBM's quantum program is among the most advanced on Earth, with its 1,121-qubit Condor processor, its error-corrected Heron chip, and the most detailed public roadmap to fault-tolerant computing by 2029, a roadmap that has, unlike nearly everything else in quantum, actually hit its milestones on schedule. An open foundry benefits the entire industry, not just IBM, and Gil is qualified precisely because he built the thing the government is now funding. But 50% of a program shaped in part by a former executive of the largest beneficiary demands formal recusal disclosure that no public record shows.
Valuation at 334x
| Company | Market Cap | FY2025 Revenue | P/S Ratio | Net Loss (Latest) |
|---|---|---|---|---|
| IonQ | $19.9B | $130M | 153x | -$510M (TTM) |
| Quantinuum | $21.3B | ~$7M* | ~3,043x | N/A (pre-IPO) |
| D-Wave | $8.9B | $24.6M | 362x | -$18.4M (Q1) |
| Rigetti | $6.4B | $7.1M | 901x | -$216.1M (FY25) |
*Quantinuum revenue estimated. P/S calculated at close prices as of June 30 through July 1, 2026; the numbers have moved since then, but the orders of magnitude have not.
Rigetti trades at 901 times revenue while losing $216 million annually on $7.1 million in sales, a revenue figure that actually declined from the prior year's $10.8 million, meaning the company is getting further from commercial viability, not closer, even as its stock price implies the opposite. D-Wave's Q1 2026 revenue was $2.9 million against an $18.4 million loss; its record $33.4 million in bookings leaned on a single $20 million university deal. At this stage, these companies' primary product is equity, not computation, and investors are buying proximity to a future that remains unpriced because it is unbuilt. Not yet, anyway — these are bets on a future that may arrive in three years or thirty, and the market has priced them as though the answer is three.
Announcement-Day Amplifier
On May 21, D-Wave surged 30%, Rigetti 30%, and IBM climbed 12%. Three smaller quantum pure-plays collectively received $300 million in proposed awards, and their combined market cap increased by approximately $5 billion in a single session, roughly $16.70 in market value for every $1 the government committed. That ratio reflects sector momentum and sentiment as much as the awards themselves. Narrative, not revenue. Commerce's announcement functioned less like an investment and more like an IV drip of institutional legitimacy into companies whose share prices are driven entirely by the story the market tells itself.
Strongest Case Against
Quantum computing is not overhyped. Quantinuum's Helios hit 99.92% two-qubit gate fidelity, Google's Willow cracked below-threshold error correction, and IBM's roadmap to fault tolerance by 2029 remains exactly on schedule. Every machine works.
What breaks down is the financial structure. Commerce is buying equity at valuations that already price in success; if quantum reaches viability and stock prices triple, the government earns a modest return, but if that upside was already embedded at 334x sales, the equity stakes produce nothing. Only one scenario lets the equity structure outperform a traditional research grant: quantum succeeds AND these specific valuations keep climbing from already-historic levels, a compound bet the government has no particular edge in making. HGP spent $3.8 billion and generated $796 billion in economic activity, a 209:1 return, but it funded basic science at universities, not equity stakes in publicly traded companies. DARPA funded open-ended research programs that accidentally created the internet, GPS, and the foundations of modern AI, not $100 million equity positions in companies already trading at triple-digit price-to-sales multiples on public exchanges.
What You Can Do
If you hold quantum stocks, understand what you own: call options on physics, not businesses. At 334x price-to-sales, the market has already priced in success that most of these companies will never deliver, which means your downside is not 20% or 50% but potentially everything. CHIPS funding de-risks survival, not viability. Size accordingly. Treat it like venture capital. Your position should be what you can afford to lose entirely, because at these multiples, total loss is not a tail risk but a base case for most names in the sector.
If you work in quantum, CHIPS funding extends runway, but Washington is hedging across five hardware modalities (superconducting, trapped ion, neutral atom, photonic, silicon spin), and history strongly suggests one or two will dominate. Companies built on the wrong qubit modality will not survive the consolidation phase, regardless of how much government support they received during the years when every approach still looked viable.
If you follow federal policy, the Gil conflict warrants formal investigation under 18 U.S.C. § 208, the criminal statute that requires executive branch officials to disqualify themselves from any particular matter in which a former employer has a financial interest, a provision that exists precisely because the situation Commerce has created is the situation Congress was trying to prevent.
Limitations
Revenue figures and market caps as of June 30–July 1, 2026. Quantinuum revenue estimated from limited Honeywell disclosures; Quantinuum's IPO prospectus did not break out quantum-specific revenue from Honeywell's broader portfolio. Three CHIPS recipients, Atom Computing, PsiQuantum, and Diraq, are private companies with no public financials, meaning the true sector-wide P/S ratio could be higher or lower depending on revenue levels they have chosen not to disclose. Letters of intent are not finalized agreements, and given the Commerce Department's history of renegotiating CHIPS awards downward after announcement, actual fund flows may differ substantially from the headline allocations published here.
The Bottom Line
The United States government is now a shareholder in nine quantum computing companies through a $2 billion program of contested legal basis, overseen in part by a former executive of the largest beneficiary, investing in an industry trading at 48 times the dot-com bubble's valuation peak. The government's track record on pre-commercial technology bets is 3-for-3 on the ones that defined entire industries, a streak that makes the CHIPS quantum play look defensible until you examine how those earlier bets were actually structured. But HGP didn't buy stock in Celera Genomics to decode the genome. DARPA didn't take a board seat at Netscape. History's best government technology investments, from the Manhattan Project to ARPANET to the Human Genome Project, were structured as open-ended research funding, not as equity trades against publicly traded companies. This one is structured as a trade, and the exit strategy remains undefined.